Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain activ... Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. 詳細を表示
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04305 | -9.21249732506 | 0.4673 | 0.47045 | 0.4004 | 85556 | 0.43922004 | CS |
4 | -0.06165 | -12.6877958428 | 0.4859 | 0.619 | 0.4004 | 188765 | 0.51833652 | CS |
12 | -0.17275 | -28.9363484087 | 0.597 | 1.09 | 0.4004 | 300946 | 0.62919471 | CS |
26 | -0.27695 | -39.4965772961 | 0.7012 | 1.1099 | 0.4004 | 255283 | 0.73702188 | CS |
52 | -0.54075 | -56.0362694301 | 0.965 | 1.87 | 0.4004 | 134246 | 0.76370456 | CS |
156 | -3.69575 | -89.7026699029 | 4.12 | 4.92 | 0.4004 | 63889 | 1.40416904 | CS |
260 | -14.53575 | -97.1641042781 | 14.96 | 19.56 | 0.4004 | 341741 | 10.32669996 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約